Related Experiment Video
Updated: Feb 3, 2026
Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
Published on: April 29, 2014
Therapeutic Sequencing in Metastatic Renal Cell Carcinoma
Manuel Caitano Maia1, Nazli Dizman1, Meghan Salgia1
1Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Abstract:
The influx of multiple novel therapeutic options in the mRCC field has brought a challenge for treatment sequencing in this disease. In the past few years, cabozantinib, nivolumab and the combination of lenvatinib and everolimus have been approved in the second-line setting. As there is no direct comparison between these agents and the studies have failed to show improved benefit among a biomarker-selected patient population, appropriate patient selection based on clinical factors for individualized therapy is critical. Herein we provide a comprehensive overview of current data from each agent through the discussion of disease biology, clinical trials, potential biomarkers and distilling future perspectives in the field.
Insights
Selecting the right treatment sequence is crucial for advanced kidney cancer (mRCC). New therapies like cabozantinib and nivolumab require careful patient selection due to a lack of direct comparisons.
Area of Science:
- Oncology
- Medical Therapeutics
Background:
- The treatment landscape for metastatic renal cell carcinoma (mRCC) has rapidly evolved with new drug approvals.
- Sequencing these novel agents presents a significant clinical challenge.
Purpose of the Study:
- To provide a comprehensive overview of current therapeutic options for second-line mRCC.
- To discuss disease biology, clinical trial data, and potential biomarkers for guiding treatment decisions.
Main Methods:
- Review of current clinical trial data for approved second-line agents.
- Discussion of disease biology and potential predictive biomarkers.
- Analysis of treatment sequencing challenges in mRCC.
Main Results:
- Several novel agents, including cabozantinib, nivolumab, and lenvatinib/everolimus, are approved for second-line mRCC.
- Direct comparative data between these agents is limited.
- Biomarker-selected populations have not consistently shown improved benefit.
Conclusions:
- Individualized patient selection based on clinical factors is critical for optimizing treatment outcomes in mRCC.
- Further research is needed to establish optimal sequencing strategies and identify predictive biomarkers.
More Related Videos
05:36Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane
Published on: February 8, 2020
06:38A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Related Concept Videos
01:17Factors Affecting Renal Clearance: Renal Impairment
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
01:13Therapeutic Index
01:20Renal Corpuscle
Glomerulus: Structure and Function
The glomerulus is a tiny, intricate network of capillaries located at the beginning of the nephron. It's enveloped by the Bowman's capsule and receives its blood supply from an afferent arteriole, which divides into numerous...
01:23Renal Clearance
Renal clearance refers to the volume of plasma cleared of a specific substance, such as creatinine, per unit of time. To measure clearance, urine samples are collected over a 24-hour period during each bladder voiding, followed by a single blood sample at the...
02:02Cis-regulatory Sequences
01:08Renal Drug Clearance: Comparison Between Renal Excretion Methods
Renal clearance is often associated with the renal glomerular filtration rate (GFR), which represents the rate at which plasma is filtered through the glomeruli in the kidney. When drug reabsorption is minimal and there is no active secretion, renal clearance is closely related to the...